



Antimicrobial Stewardship in Australian Health Care

2018

Published by the Australian Commission on Safety and Quality in Health Care
Level 5, 255 Elizabeth Street, Sydney NSW 2000

Phone: (02) 9126 3600

Fax: (02) 9126 3613

Email: mail@safetyandquality.gov.au

Website: www.safetyandquality.gov.au

ISBN: 978-1-925665-40-6

© Australian Commission on Safety and Quality in Health Care 2018

All material and work produced by the Australian Commission on Safety and Quality in Health Care (the Commission) is protected by copyright. The Commission reserves the right to set out the terms and conditions for the use of such material.

As far as practicable, material for which the copyright is owned by a third party will be clearly labelled. The Commission has made all reasonable efforts to ensure that this material has been reproduced in this publication with the full consent of the copyright owners.

With the exception of any material protected by a trademark, any content provided by third parties and where otherwise noted, all material presented in this publication is licensed under a [Creative Commons Attribution–NonCommercial–NoDerivatives 4.0 International licence](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Enquiries about the licence and any use of this publication are welcome and can be sent to communications@safetyandquality.gov.au.

The Commission's preference is that you attribute this publication (and any material sourced from it) using the following citation:

Australian Commission on Safety and Quality in Health Care. *Antimicrobial Stewardship in Australian Health Care 2018*. Sydney: ACSQHC; 2018

Disclaimer

The content of this document is published in good faith by the Commission for information purposes. The document is not intended to provide guidance on particular healthcare choices. You should contact your healthcare provider for information or advice on particular healthcare choices.

This document includes the views or recommendations of its authors and third parties. Publication of this document by the Commission does not necessarily reflect the views of the Commission, or indicate a commitment to a particular course of action. The Commission does not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this document.

Antimicrobial Stewardship in Australian Health Care

2018

Acknowledgements

Antimicrobial Stewardship in Australian Health Care 2018 has been developed through the contributions of many individuals and organisations who are committed to improving antimicrobial use in hospitals and reducing the risk of harm to patients from inappropriate antimicrobial prescribing.

The Australian Commission on Safety and Quality in Health Care wishes to thank the following contributing authors for their expertise and time given to the writing of this publication:

- Dr Tara Anderson – Infectious Diseases Physician and Clinical Microbiologist, Medical Advisor – Infection Prevention and Control, Royal Hobart Hospital, and Specialist Medical Advisor – Tasmanian Infection Prevention and Control Unit (particularly Chapter 2)
- Dr Noleen Bennett – National Centre for Antimicrobial Stewardship (particularly Chapter 12)
- Associate Professor Kirsty Buising – National Centre for Antimicrobial Stewardship (particularly Chapters 3 and 6)
- Clinical Associate Professor Susan Benson – PathWest Laboratory Medicine, Western Australian Department of Health and University of Western Australia (particularly Chapter 9)
- Dr Celia Cooper – SA Pathology, SA Health (particularly Chapters 5 and 8)
- Dr Jonathan Dartnell – NPS MedicineWise (particularly Chapters 7 and 10)
- Ms Margaret Duguid – Australian Commission on Safety and Quality in Health Care (contribution to all Chapters)
- Conjoint Associate Professor John Ferguson – Hunter New England Local Health District (particularly Chapter 9)
- Ms Fiona Gotterson – Australian Commission on Safety and Quality in Health Care (particularly Chapters 3, 5 and 12)
- Dr David Kong – Ballarat Health Services and Centre for Medicine Use and Safety, Monash University (particularly Chapter 11)
- Associate Professor David Looke – Infectious Diseases Physician and Clinical Microbiologist, Princess Alexandra Hospital; and Associate Professor, University of Queensland (particularly Chapter 6)
- Professor Graeme Nimmo – Pathology Queensland, Queensland Health (particularly Chapter 9)
- Professor Lisa Pulver – NPS MedicineWise (particularly Chapters 7 and 10)
- Professor Debra Rowett – NPS MedicineWise (particularly Chapters 7 and 10)
- Professor Karin Thursky – National Centre for Antimicrobial Stewardship (particularly Chapter 4)
- Professor John Turnidge – Australian Commission on Safety and Quality in Health Care (particularly Chapters 1 and 3)
- Dr Helen Van Gessel – Albany Hospital (particularly Chapter 2)
- Dr Morgyn Warner – SA Pathology, SA Health (particularly Chapter 1)
- Dr Jeanie Yoo – NPS MedicineWise (particularly Chapter 10).

The Commission also wishes to extend its thanks to the following individuals who have provided their considered advice in the review of the content of this book:

- Dr Philippa Binns – public health physician and general practitioner
- Professor Chris Del Mar – Centre for Research in Evidence-Based Practice, Bond University
- Dr Kylie Easton – NPS MedicineWise
- Associate Professor Thomas Gottlieb - Senior Staff Specialist, Microbiology & Infectious Diseases, Concord Hospital
- Dr Malene Hansen – Centre for Research in Evidence-Based Practice, Bond University
- Ms Dorothy Harrison – consumer representative reviewer
- Ms Aine Heaney – NPS MedicineWise
- Ms Elaine Lum – Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology
- Dr Amanda McCullough – Centre for Research in Evidence-Based Practice, Bond University
- Dr Geoffrey Playford - Director, Infection Management Services, Princess Alexandra Hospital
- Associate Professor Owen Robinson - Infectious Diseases Physician, Royal Perth Hospital

- Ms Vanessa Simpson – NPS MedicineWise
- Dr Andrew Staib - Emergency Medicine, Princess Alexandra Hospital
- Dr Clair Sullivan - Consultant Endocrinologist and Medical Informatician, Princess Alexandra Hospital.

A number of Commission staff were also involved in the writing and review of this publication, and the Commission wishes to acknowledge:

- Ms Debbie Carter
- Professor Marilyn Cruickshank
- Dr Nicola Dunbar
- Dr Robert Herkes
- Ms Eliza McEwin
- Adjunct Professor Kathy Meleady
- Adjunct Professor Debora Picone AM
- Ms Naomi Poole
- Ms Lucia Tapsall
- Mr Michael Wallace.

In addition, the Commission wishes to acknowledge the members of the Society of Hospital Pharmacists of Australia Infectious Diseases Committee of Specialty Practice for their contribution in reviewing this publication; and the staff of Biotext for their expert review, editing and design services.

Contents

Acknowledgements	iii
Summary	1
Key issues	3
The challenge	3
The response	3
Australian framework for AMS	3
Essential elements of antimicrobial stewardship	3
This publication	4
Aim	4
Structure	4
Chapter 1: Evidence for antimicrobial stewardship	7
Acronyms and abbreviations	10
1.1 Introduction	11
1.2 Challenge and impact of antimicrobial resistance	12
1.2.1 Association between antimicrobial use and resistance	12
1.2.2 Consequences of antimicrobial resistance	13
1.3 Australian framework for antimicrobial stewardship	14
1.3.1 National standards and guidelines	14
1.3.2 National Antimicrobial Resistance Strategy	17
1.3.3 Antimicrobial stewardship in the states and territories	17
1.3.4 Therapeutic Guidelines	17
1.3.5 Surveillance of antimicrobial use and resistance in Australia	18
1.3.6 Education and awareness raising	19
1.3.7 Antimicrobial stewardship research	20
1.3.8 Professional societies and organisations	20
1.4 Antimicrobial use	21
1.4.1 Factors contributing to unnecessary and inappropriate antimicrobial use	21
1.4.2 Antimicrobial use in Australia	21
1.4.3 Harmful effects of antimicrobial use	21
1.5 Antimicrobial stewardship	22
1.5.1 Effective antimicrobial stewardship	22
1.5.2 Evidence to support the benefits of antimicrobial stewardship	24
1.5.3 Unintended consequences of antimicrobial stewardship programs	27
References	29
Appendix A: Examples of antimicrobial stewardship (AMS) activities and resources in Australian states and territories	34

Chapter 2: Establishing and sustaining an antimicrobial stewardship program	35
Acronyms and abbreviations	38
2.1 Introduction	39
2.2 Essential elements of antimicrobial stewardship programs	40
2.3 Structure and governance	41
2.3.1 Safety and quality improvement	41
2.3.2 Governance	41
2.3.3 Executive leadership	44
2.3.4 Clinical leadership	44
2.4 Antimicrobial stewardship committee and team	45
2.4.1 Antimicrobial stewardship committee	45
2.4.2 Antimicrobial stewardship team	48
2.5 Antimicrobial stewardship program plan	49
2.5.1 Assessing readiness to implement an antimicrobial stewardship program or intervention	49
2.5.2 Reviewing existing policies and prescribing guidelines	53
2.5.3 Reviewing local data on antimicrobial use and resistance	55
2.5.4 Determining priority areas for antimicrobial stewardship activities	56
2.5.5 Identifying effective interventions	57
2.5.6 Defining measurable goals and outcomes	58
2.5.7 Documenting and implementing the antimicrobial stewardship plan	59
2.5.8 Educating the workforce	59
2.5.9 Developing and implementing a communication plan	60
2.6 Sustaining the antimicrobial stewardship program	60
Resources	61
References	63
Appendix A: Examples of successful and sustained antimicrobial stewardship programs	66
Chapter 3: Strategies and tools for antimicrobial stewardship	75
Acronyms and abbreviations	78
3.1 Introduction	79
3.2 Prescribing guidelines	81
3.2.1 National guidelines	81
3.2.2 Local guidelines	81
3.2.3 Promoting guideline uptake	82
3.2.4 Tools and resources to support guideline implementation	82
3.2.5 Education and feedback	83
3.2.6 Antimicrobial stewardship care bundles	83
3.3 Formularies and approval systems	83
3.3.1 National formulary	83
3.3.2 State and territory formularies	84
3.3.3 Hospital formularies	84
3.3.4 Antimicrobial approval systems	85

3.4 Post-prescription reviews	87
3.4.1 Who should perform reviews in hospitals?	87
3.4.2 Which patients should be reviewed?	89
3.4.3 What should be included in the feedback?	89
3.4.4 How should feedback be provided?	89
3.4.5 Prescription review at transitions of care	90
3.4.6 Post-prescription reviews in the community setting	90
3.5 Point-of-care interventions	91
3.5.1 Directing therapy based on results from microscopy and other rapid tests	91
3.5.2 Directing therapy based on culture and susceptibility test results	91
3.5.3 Optimising dosing	91
3.5.4 Limiting toxicity	92
3.5.6 Changing the duration of therapy	92
3.5.7 Switching from intravenous to oral delivery	92
3.5.8 Escalating to formal expert clinical review	93
Resources	94
References	95
 Chapter 4: Information technology to support antimicrobial stewardship	 99
Acronyms and abbreviations	102
4.1 Introduction	103
4.2 Electronic clinical decision support systems	104
4.2.1 Passive decision support systems and smartphone apps	105
4.2.2 Electronic approval systems	108
4.2.3 Electronic surveillance and infection prevention systems	109
4.2.4 Electronic prescribing and medication management systems	110
4.2.5 Advanced decision support systems	111
4.2.6 Implementing electronic clinical decision support systems for antimicrobial stewardship	112
4.2.7 Electronic clinical decision support in primary care	113
4.3 Data collection and reporting	114
4.4 Telehealth	115
Resources	117
References	118
 Chapter 5: Antimicrobial stewardship education for clinicians	 123
Acronyms and abbreviations	126
5.1 Introduction	127
5.2 Key elements of antimicrobial stewardship education	128
5.2.1 Audiences	128
5.2.2 Principles of education on antimicrobial stewardship	129
5.2.3 Antimicrobial stewardship competencies and standards	129

5.2.4	Influence of the pharmaceutical industry	131
5.2.5	Evaluation of educational activities	132
5.3	Antimicrobial stewardship education for different groups and stages	132
5.3.1	Undergraduate training	132
5.3.2	Early-career development	133
5.3.3	Continuing education and professional development	134
5.3.4	Education and training for antimicrobial stewardship teams	136
5.3.5	Specialist training	137
5.4	Education resources	137
5.4.1	Guidelines	137
5.4.2	Websites and online learning resources	137
5.4.3	Educators	138
	Resources	139
	References	140
Appendix A:	Managing conflicts of interest and relationships with the pharmaceutical industry – further reading and links	143
Appendix B:	Example of a ‘Did you know’ email for clinicians	144
Chapter 6: Measuring performance and evaluating antimicrobial stewardship programs		147
Acronyms and abbreviations		150
6.1	Introduction	151
6.2	Key elements of antimicrobial stewardship measurement	152
6.2.1	What should be measured?	152
6.2.2	Measurement approaches	152
6.3	Structure measures	152
6.3.1	Hospitals	152
6.3.2	Community	154
6.4	Process measures	154
6.5	Outcome measures	155
6.5.1	Improved patient outcomes	156
6.5.2	Improved patient safety	156
6.5.3	Reduced resistance	156
6.5.4	Reduced costs	157
6.5.5	Qualitative and other related measures of program activity	157
6.6	Balancing measures	157
6.7	Surveillance of antimicrobial use	158
6.7.1	Measuring the volume of antimicrobial use in hospitals	158
6.7.2	Measuring the volume of antimicrobial use in the community	160
6.7.3	Reporting and monitoring use data at the local level	161
6.8	Auditing the quality of antimicrobial prescribing	164
6.8.1	Auditing prescribing in hospitals	164

6.8.2	Auditing prescribing in the community	166
6.8.3	Quality improvement audits	167
6.9	Reporting, feedback and use of data	168
6.9.1	Health service organisation reports	168
6.9.2	State and territory reports	168
6.9.3	National reports	168
6.9.4	Use of data for benchmarking	169
Resources		171
References		172
Chapter 7: Involving consumers in antimicrobial stewardship		177
Acronyms and abbreviations		180
7.1	Introduction	181
7.2	Consumer awareness and expectations	182
7.2.1	Consumer understanding of when antimicrobials are needed	182
7.2.2	Consumer awareness and understanding of antimicrobial resistance	182
7.2.3	Previous experience of antimicrobials	183
7.3	Key messages and communication	183
7.3.1	Reassurance	183
7.3.2	Health literacy	183
7.3.3	Communication with consumers in different settings and circumstances	185
7.4	Consumer resources and tools	186
7.4.1	Before the consultation	186
7.4.2	During the consultation	187
7.4.3	After the consultation	188
7.4.4	Reaching and engaging consumers nationally	188
7.4.5	Antibiotic Awareness Week	190
Resources		191
References		192
Chapter 8: Role of the infectious diseases service in antimicrobial stewardship		195
Acronyms and abbreviations		198
8.1	Introduction	199
8.2	Leadership	199
8.2.1	Participating in the antimicrobial stewardship team and committees	200
8.2.2	Implementing and maintaining antimicrobial policies and guidelines	201
8.3	Expert advice	201
8.3.1	Specific situations requiring infectious diseases physician expertise	202
8.3.2	Support for external organisations	203
8.4	Support for formularies and approval systems	204

8.4.1	Formularies	204
8.4.2	Approval systems	204
8.5	Prescription review with feedback	205
8.5.1	Antimicrobial stewardship team rounds	205
8.5.2	Conflicting advice	205
8.6	Monitoring antimicrobial use and evaluating interventions	206
8.7	Liaison	207
8.7.1	Liaison within hospitals	207
8.7.2	Interacting with the pharmaceutical industry	207
8.8	Role in education	208
	Resources	209
	References	209

Chapter 9: Role of the clinical microbiology service in antimicrobial stewardship		213
Acronyms and abbreviations		216
9.1	Introduction	217
9.2	Overview of the diagnostic testing process	217
9.3	Pre-analytical phase: microbiology process	218
9.3.1	Selecting diagnostic tests	218
9.3.2	Collecting and transporting samples	220
9.3.3	Commenting on specimen quality	221
9.4	Analytical phase: microbiological analytical practice	221
9.4.1	Rapid diagnostics and testing	221
9.4.2	Antimicrobial susceptibility testing	222
9.5	Post-analytical phase: microbiology reporting	222
9.5.1	Timeliness of test reporting and integration with antimicrobial stewardship programs	222
9.5.2	Reporting and interpreting results	222
9.5.3	Cascade reporting	224
9.5.4	Communicating critical results	225
9.6	Specific situations that need clinical microbiology service expertise	225
9.6.1	Support for high-risk units	225
9.6.2	Cumulative antibiogram analysis	226
9.6.3	Signal and critical antimicrobial resistances (CARs)	226
9.6.4	Therapeutic drug monitoring and review	228
9.6.5	Linking microbiology results with electronic prescribing	228
9.6.6	Measuring performance of the clinical microbiology service as part of the antimicrobial stewardship program	228
9.7	Role in education	229
	Resources	230
	References	231

Chapter 10: Role of prescribers in antimicrobial stewardship	237
Acronyms and abbreviations	240
10.1 Introduction	241
10.2 Prescriber concerns and influences	242
10.2.1 Prescriber perspectives on antimicrobial resistance	242
10.2.2 Policies and guidelines	242
10.2.3 Diagnostic uncertainty	243
10.2.4 Influence of others	243
10.2.5 Prescribers in aged care	244
10.2.6 Non-medical prescribers	244
10.3 Prescriber strategies	245
10.3.1 Antimicrobial stewardship prescribing principles	245
10.3.2 Prescribing in specific situations	246
10.4 Prescriber resources and tools	247
10.4.1 Guidelines and antimicrobial information	247
10.4.2 Antimicrobial Stewardship Clinical Care Standard	247
10.4.3 Education and professional development	247
Resources	248
References	249

Chapter 11: Role of the pharmacist and pharmacy services in antimicrobial stewardship	253
Acronyms and abbreviations	256
11.1 Introduction	257
11.2 Pharmacists and antimicrobial stewardship	257
11.2.1 Activities in different settings	258
11.2.2 Pharmacy managers	261
11.2.3 Roles of antimicrobial stewardship pharmacists	262
11.3 Leadership	262
11.3.1 Promoting uptake and compliance with national standards for antimicrobial stewardship	263
11.3.2 Developing and maintaining antimicrobial guidelines	263
11.4 Expert advice	263
11.4.1 Providing expert advice to clinicians, patients and carers	263
11.4.2 Participating in antimicrobial stewardship ward rounds	263
11.4.3 Initiating point-of-care interventions	264
11.5 Formularies and approval systems	264
11.6 Monitoring antimicrobial use and evaluating interventions	264
11.7 Liaison	265
11.8 Education	265
11.8.1 Antimicrobial stewardship education for pharmacists	265
11.8.2 Pharmacists' role in education	267

Resources	268
References	269
Appendix A: Examples of training and educational opportunities for AMS pharmacists	271
Chapter 12: Role of nurses, midwives and infection control practitioners in antimicrobial stewardship	273
Acronyms and abbreviations	276
12.1 Introduction	277
12.2 Nursing and midwifery practice and antimicrobial stewardship	277
12.3 Facilitating nursing and midwifery involvement	280
12.3.1 Planning for nursing and midwifery involvement	280
12.3.2 Promoting a safety culture	282
12.3.3 Education	283
12.3.4 Resources and tools	284
12.4 Advanced and specialist practice roles	285
12.4.1 Nurse practitioners	285
12.4.2 Infection control practitioners	286
Resources	289
References	290
Glossary	293
Glossary	295
References	303